Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276288 | 0.73 | RECQL (0.48) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL47226 | 0.71 | CYP1A2 (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL18877 | 0.71 | RECQL (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL3535213 | 0.71 | RECQL (0.52) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL61456 | 0.71 | RECQL (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL13647386 | 0.71 | RECQL (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL329140 | 0.71 | RECQL (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL787026 | 0.71 | RECQL (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| SCHEMBL2010731 | 0.71 | RECQL (0.47) | RECQLCYP1A2KMOADRA2AADRA2B | |
| Water SCHEMBL2123597 | 0.71 | CYP1A2 (0.47) | RECQLCYP1A2KMOADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | claimed |
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-05-05 | — | — | US | claimed |
| CN-113166153-A | Fused pyrazine derivatives as A2A/A2B inhibitors | 因赛特公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3818063-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-05-12 | — | — | EP | claimed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | claimed |
| US-8680290-B2 | Isoxazoline derivatives and their use as herbicides | SYNGENTA LIMITED (GB) | 2014-03-25 | — | — | US | claimed |
| CN-102143940-A | Cyclohexyl amide derivatives as CRF-1 receptor antagonists and uses thereof | NOVARTIS AG | 2011-08-03 | — | — | CN | claimed |
| CN-101052628-B | Isoxazoline derivatives and herbicidal use thereof | SYNGENTA LTD | 2011-07-27 | — | — | CN | claimed |
| CN-102112449-A | Phenyl or pyridinyl substituted indazoles derivatives | ASTRAZENECA AB | 2011-06-29 | — | — | CN | claimed |
| EP-1789401-B1 | ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA LTD (GB) | 2010-03-03 | — | — | EP | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| CN-1192209-A | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas | DU PONT MERCK PHARMA (US) | 1998-09-02 | — | — | CN | claimed |
| CN-88102628-A | Novel substituted silylalkyleneamines | — | 1988-11-30 | — | — | CN | claimed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117715893-A | Combination therapy comprising a MAT2A inhibitor and a PRMT type II inhibitor | 伊迪亚生物科学公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-86103278-A | The method for preparing heterocyclic amide derivative | — | 1986-12-17 | — | — | CN | disclosed |
| CN-85108623-A | Preparation has the novel method of the heterocycleamide of medical active | — | 1986-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | RECQL 1168/4885CYP1A2 162/4885KMO 682/4885 |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | RECQL 1168/4885CYP1A2 162/4885KMO 682/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | RECQL 2727/4885CYP1A2 4174/4885KMO 3833/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | RECQL 1168/4885CYP1A2 162/4885KMO 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.